Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

Cited by (536)

Items 101–200 of 536

1. Biomarkers for Managing Neurodegenerative Diseases
   Lara Cheslow, Adam Eugene Snook, Scott Arthur Waldman · 2024 · Biomolecules
2. Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases
   Peter Bloomingdale, Suruchi Bakshi, Christian Maaß, Eline van Maanen, César Pichardo‐Almarza, Daniela Bumbaca Yadav, Piet Hein van der Graaf, Nitin Mehrotra · 2021 · Journal of Pharmacokinetics and Pharmacodynamics
3. “Real world” eligibility for aducanumab
   Canevelli, Marco, Rossi, Paolo Dionigi, Astrone, Paolo, Consorti, Ernesto, Vanacore, Nicola, Cesari, Matteo · 2021 · Journal of the American Geriatrics Society
4. Vascular contributions to cognitive impairment and dementia: the emerging role of 20-HETE
   Ezekiel Gonzalez‐Fernandez, Yedan Liu, Alexander P. Auchus, Fan Fan, Richard J. Roman · 2021 · Clinical Science
5. Detection of protein oligomers with nanopores
   Robert I. Horne, Sarah E. Sandler, Michele Vendruscolo, Ulrich F. Keyser · 2025 · Nature Reviews Chemistry
6. Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?
   Serena Silvestro, Andrea Valeri, Emanuela Mazzon · 2022 · International Journal of Molecular Sciences
7. Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
   Taha Basit Ameen, Syeda Naveera Kashif, Syed Muhammad Iraj Abbas, Kulsoom Babar, Syed Muhammad Sinaan Ali, Abdul Raheem · 2024 · The Egyptian Journal of Neurology Psychiatry and Neurosurgery
8. Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors
   Kouta Ito, Rick Chapman, Steven D. Pearson, Ali Tafazzoli, Kristine S. Yaffe, Jerry H. Gurwitz · 2021 · JAMA Network Open
9. Lessons from antiamyloid-β immunotherapies in Alzheimer's disease
   Germán Plascencia‐Villa, George L. Perry · 2023 · Handbook of clinical neurology
10. A2A Adenosine Receptor as a Potential Biomarker and a Possible Therapeutic Target in Alzheimer’s Disease
    Stefania Gessi, Tino Emanuele Poloni, Giulia Negro, Katia Varani, Silvia Pasquini, Fabrizio Vincenzi, Pier Andrea Borea, Stefania Merighi · 2021 · Cells
11. Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer’s Disease Treatment
    Mungyo Jung, Hyeongseop Kim, Jung Won Hwang, Yejoo Choi, Mikyung Kang, Cheesue Kim, Jihye Hong, Na Kyung Lee, Sangjun Moon, Jong Wook Chang et al. · 2023 · Nano Letters
12. Subjective cognitive decline is a better marker for future cognitive decline in females than in males
    Michael D. Oliver, Cassandra Morrison, Farooq Kamal, Jillian Graham, Mahsa Dadar · 2022 · Alzheimer s Research & Therapy
13. Emerging Links between Cerebral Blood Flow Regulation and Cognitive Decline: A Role for Brain Microvascular Pericytes
    Tong-Yao You, Qiang Dong, Mei Cui · 2022 · Aging and Disease
14. Comparison of relative change with effect size metrics in Alzheimer’s disease clinical trials
    Terry E. Goldberg, Seonjoo Lee, Davangere P. Devanand, Lon S. S. Schneider · 2023 · Journal of Neurology Neurosurgery & Psychiatry
15. Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment
    Haruki Koike, Yohei Iguchi, Kentaro Sahashi, Masahisa Katsuno · 2021 · Molecules
16. A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro
    Isabelle Aillaud, Senthilvelrajan Kaniyappan, RamReddy Chandupatla, Lisa Marie Ramirez, Sewar Alkhashrom, Jutta Eichler, Anselm H. C. Horn, Markus Zweckstetter, Eckhard Mandelkow�, Heinrich Sticht et al. · 2022 · Alzheimer s Research & Therapy
17. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
    Bruno Dutra Arbo, Lúcia Emanueli Schimith, Michele Goulart dos Santos, Mariana Appel Hort · 2022 · European Journal of Pharmacology
18. Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
    Hannah Waleed Haddad, Garett W. Malone, Nicholas J. Comardelle, Arielle E. Degueure, Salomon Poliwoda, Rachel J. Kaye, Kevin Sean Murnane, Adam Marc Kaye, Alan D. Kaye · 2022 · Health Psychology Research
19. The emerging neuroprotective roles of exerkines in Alzheimer’s disease
    Tayná Rody, Julia A. De Amorim, Fernanda G. De Felice · 2022 · Frontiers in Aging Neuroscience
20. Conventional Versus New Treatment: Comparing the Effects of Acetylcholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonist With Aducanumab
    Elysia Chin, Ecler Ercole Jaqua, Mary Safaeipour, Tyler Ladue · 2022 · Cureus
21. Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms
    Albert Garcia‐Romeu, Sean Darcy, Hillary Jackson, Toni White, Paul B. Rosenberg · 2021 · Current topics in behavioral neurosciences
22. Network-based stage-specific drug repurposing for Alzheimer’s disease
    Kyriaki Savva, Margarita Zachariou, Marilena M. Bourdakou, Nikolas Dietis, George M. Spyrou · 2022 · Computational and Structural Biotechnology Journal
23. Prescribing Aducanumab in the Face of Meager Efficacy and Real Risks
    David S. Knopman, Joel S. Perlmutter · 2021 · Neurology
24. On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease
    Ján Kriška, Zuzana Heřmanová, Tomáš Knotek, Jana Turečková, Miroslava Anděrová · 2021 · International Journal of Molecular Sciences
25. A dynamical systems approach for multiscale synthesis of Alzheimer’s pathogenesis
    Jennifer L. Rollo, John W. Crawford, John Hardy · 2023 · Neuron
26. Domino-like effect of C112R mutation on ApoE4 aggregation and its reduction by Alzheimer’s Disease drug candidate
    Nemergut, Michal, Marques, Sérgio M., Uhrik, Lukas, Vanova, Tereza, Nezvedova, Marketa, Gadara, Darshak Chandulal, Jha, Durga, Tulis, Jan, Novakova, Veronika, Planas-Iglesias, Joan et al. · 2023 · Molecular Neurodegeneration
27. What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease
    Michelle Jin, James McC. Noble · 2024 · eNeuro
28. AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery
    Coralie Di Scala, Nicholas Armstrong, Henri Chahinian, Éric Chabrière, Jacques Fantini, Nouara Yahi · 2022 · International Journal of Molecular Sciences
29. Active immunotherapy reduces NOTCH3 deposition in brain capillaries in a CADASIL mouse model
    Daniel V. Oliveira, Kirsten Coupland, Wenchao Shao, Shaobo Jin, Francesca Del Gaudio, Sailan Wang, Rhys Fox, Julie W. Rutten, Johan Sandin, Henrik Zetterberg et al. · 2022 · EMBO Molecular Medicine
30. The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [ 18 F]MK6240 Tau PET in Target Regions
    Cécile Tissot, Stijn Servaes, Firoza Zubeida Lussier, João Pedro Ferrari‐Souza, Joseph Therriault, Pâmela C.L. Ferreira, Gleb Bezgin, Bruna Bellaver, Douglas Teixeira Leffa, Sulantha Sanjeewa Mathotaarachchi et al. · 2022 · Journal of Nuclear Medicine
31. Cholesterol Metabolism in Neurodegenerative Diseases
    Keqiang He, Zhiwei Zhao, Juan Zhang, Dingfeng Li, Sheng Wang, Qiang Liu · 2024 · Antioxidants and Redox Signaling
32. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer’s Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial
    Xue Hua, Kevin J. Church, William Walker, Philippe L’Hostis, Geoffrey Viardot, Philippe Danjou, Suzanne Hendrix, Hans J. Moebius · 2022 · Journal of Alzheimer s Disease
33. Nanoparticles-based anti-aging treatment of Alzheimer’s disease
    Jianjian Chu, Wenbo Ji, Jianhua Zhuang, Baofeng Gong, Xiaohan Chen, Wenbin Cheng, Wendanqi Liang, Genru Li, Jie Gao, You Yin · 2022 · Drug Delivery
34. A Focused Review on Cognitive Improvement by the Genus Salvia L. (Sage)—From Ethnopharmacology to Clinical Evidence
    Abdülselam Ertaş, Serkan Yiğitkan, İlkay Erdoğan Orhan · 2023 · Pharmaceuticals
35. Flanking regions, amyloid cores, and polymorphism: the potential interplay underlying structural diversity
    Anukool A. Bhopatkar, Rakez Kayed · 2023 · Journal of Biological Chemistry
36. A low-dimensional cognitive-network space in Alzheimer’s disease and frontotemporal dementia
    Lorenzo Pini, Siemon C. de Lange, Francesca Benedetta Pizzini, Ilaria Boscolo Galazzo, Rosa Manenti, Maria Cotelli, Samantha Galluzzi, Maria Sofia Cotelli, Maurizio Corbetta, Martijn P. van den Heuvel et al. · 2022 · Alzheimer s Research & Therapy
37. A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer’s Disease
    Yeo-Teh, Nicole Shu Ling, Tang, Bor Luen · 2023 · Science and Engineering Ethics
38. Blood pressure variability and plasma Alzheimer’s disease biomarkers in older adults
    Sible, Isabel J., Yew, Belinda, Jang, Jung Yun, Alitin, John Paul M., Li, Yanrong, Gaubert, Aimée, Nguyen, Amy, Dutt, Shubir, Blanken, Anna E., Ho, Jean K. et al. · 2022 · Scientific Reports
39. Successes and failures: the latest advances in the clinical development of amyloid–β–targeting monoclonal antibodies for treating Alzheimer's disease
    Francesco Panza, Vittorio Dibello, Rodolfo Sardone, Roberta Zupo, Fabio Castellana, Ivana Leccisotti, Maria Claudia Moretti, Mario Altamura, Antonello Bellomo, Antonio Daniele et al. · 2025 · Expert Opinion on Biological Therapy
40. Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer’s disease
    Carla Cuní‐López, Romal Stewart, Lotta E. Oikari, Tam Hong Nguyen, Tara Laurine Roberts, Yifan Sun, Christine Cong Guo, Michelle K. Lupton, Anthony Robert White, Hazel Quek · 2024 · Journal of Neuroinflammation
41. Neurodegenerative Diseases: New Hopes and Perspectives
    Mohammad Aadil Bhat, Suneela Sunil Dhaneshwar · 2023 · Current Molecular Medicine
42. Causal cardiovascular risk factors for dementia: insights from observational and genetic studies
    Emilie Westerlin Kjeldsen, Ruth Frikke‐Schmidt · 2024 · Cardiovascular Research
43. Advances in Alzheimer's therapy: Exploring neuropathological mechanisms to revolutionize the future therapeutic landscape
    Vrashabh V. Sugandhi, Dnyandev G. Gadhave, Akanksha Ravindra Ugale, Nilesh. N. Kulkarni, Sopan Nangare, Harshal P. Patil, Seeprarani Rath, Rahul Saxena, Amol Lavate, Apeksha T. Patel et al. · 2025 · Ageing Research Reviews
44. Polyphenols and Alzheimer's Disease: A Review on Molecular and Therapeutic Insights With In Silico Support
    Guifei Chen, Yan A. Su, Siyu Chen, Tiandong Lin, Xueying Lin · 2025 · Food Science & Nutrition
45. Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data
    Poul Flemming Høilund‐Carlsen, Abass A. Alavi · 2021 · Journal of Alzheimer s Disease
46. Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
    Vyronia Vassilakopoulou, Chrysoula‐Evangelia Karachaliou, Alexandra Evangelou, Christos C. Zikos, Evangelia Livaniou · 2021 · Vaccines
47. Impact of the Cannabinoid System in Alzheimer's Disease
    Shuangtao Li, Yuanbing Huang, Lijun Yu, Xiaoyu Ji, Jie Wu · 2022 · Current Neuropharmacology
48. Aducanumab: A new hope in Alzheimer's disease
    Rouchan Ali, Ghanshyam Das Gupta, Pooja A. Chawla · 2022 · Health Sciences Review
49. Manipulation of the diet–microbiota–brain axis in Alzheimer’s disease
    Daniel D. Lee, Virginia M.‐Y. Lee, Seong Kwon Hur · 2022 · Frontiers in Neuroscience
50. Cathepsin B Deficiency Improves Memory Deficits and Reduces Amyloid-β in hAβPP Mouse Models Representing the Major Sporadic Alzheimer’s Disease Condition
    Gregory Hook, Mark S. Kindy, VIVIAN Y. H. HOOK · 2023 · Journal of Alzheimer s Disease
51. Aducanumab in Alzheimer’s Disease: A Critical Update
    Sumel Ashique, Ekta Sirohi, Shubneesh Kumar, Mohd Rihan, Neeraj Mishra, Shvetank Bhatt, Rupesh Kumar Gautam, Sachin Kumar Singh, Gaurav Gupta, Dinesh Kumar Chellappan et al. · 2023 · Current Medicinal Chemistry
52. A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer’s Disease Spectrum
    Noemi Massetti, Mirella Russo, Raffaella Franciotti, Davide Nardini, Giorgio Maria Mandolini, Alberto Granzotto, Manuela Bomba, Stefano Delli Pizzi, Alessandra Mosca, Reinhold Scherer et al. · 2021 · Journal of Alzheimer s Disease
53. The Transcranial Light Therapy Improves Synaptic Plasticity in the Alzheimer’s Disease Mouse Model
    Débora Buendía, Tatiana Guncay, Macarena Oyanedel, Makarena Lemus, Alejandro Weinstein, Álvaro O. Ardiles, José Luis Marcos, Adriana Barrinha Fernandes, Renato Amaro Zângaro, Pablo Muñoz · 2022 · Brain Sciences
54. Amyloid futures in the expanding pathology of brain aging and dementia
    Max Andrew Thorwald, Justine A. Silva, Elizabeth Head, Caleb E. Finch · 2022 · Alzheimer s & Dementia
55. People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcare
    Karin E. Wahlberg, Bengt G. Winblad, Amanda Cole, William L. Herring, Joakim Ramsberg, Ilona Torontali, Pieter Jelle Visser, Anders B. Wimo, Lieve Wollaert, Linus Jönsson · 2023 · Journal of Internal Medicine
56. Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease
    Parrocha, Chelsea Marie T., Nowick, James S. · 2023 · Peptide Science
57. Under-Represented Populations Left Out of Alzheimer’s Disease Treatment with Aducanumab: Commentary on Ethics
    Sanjana P. Padala, Brandon Courtney Yarns · 2022 · Journal of Alzheimer s Disease Reports
58. A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
    Katherine O. Kopp, Margaret E. Greer, Elliot J. Glotfelty, Shih‐Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson, Nigel H. Greig · 2023 · Biomolecules
59. Neuronanomedicine for Alzheimer’s and Parkinson’s disease: Current progress and a guide to improve clinical translation
    India Boyton, Stella M. Valenzuela, Lyndsey E. Collins‐Praino, Andrew Care · 2023 · Brain Behavior and Immunity
60. Effect of altered gene expression in lipid metabolism on cognitive improvement in patients with Alzheimer’s dementia following fecal microbiota transplantation: a preliminary study
    Jun‐Seob Kim, Hyelim Park, Jung Hwan Lee, Jongbeom Shin, Boram Cha, Kye Sook Kwon, Yong Woon Shin, Yerim Kim, Yeo Jin Kim, Jong Seok Bae et al. · 2024 · Therapeutic Advances in Neurological Disorders
61. Auditory gamma-band entrainment enhances default mode network connectivity in dementia patients
    Mojtaba Lahijanian, Hamid K. Aghajan, Zahra Vahabi · 2024 · Scientific Reports
62. Stimulating myelin restoration with BDNF: a promising therapeutic approach for Alzheimer's disease
    Ioanna Zota, Konstantina Chanoumidou, Achille Gravanis, Ioannis Charalampopoulos · 2024 · Frontiers in Cellular Neuroscience
63. Complement as a powerful “influencer” in the brain during development, adulthood and neurological disorders
    Tiffany J. Petrisko, Ángela Gómez-Arboledas, Andrea J. Tenner · 2021 · Advances in immunology
64. Traditional East Asian Herbal Medicine Treatment for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
    Ji-Eun Lee, Seungwon Kwon, Chul Jin, Seung‐Yeon Cho, Seong-Uk Park, Woo‐Sang Jung, Sang‐Kwan Moon, Jung‐Mi Park, Chang‐Nam Ko, Ki‐Ho Cho · 2022 · Pharmaceuticals
65. Reversal of Lipid Metabolism Dysregulation by Selenium and Folic Acid Co-Supplementation to Mitigate Pathology in Alzheimer’s Disease
    Zhonghao Zhang, Xian-Chun Cao, Jiaying Peng, Shaoling L. Huang, Chen Chen, Shi-Zheng Jia, Jiazuan Ni, Guo-Li Song · 2022 · Antioxidants
66. Neuroprotection of Triptolide against Amyloid-Beta1-42-induced toxicity via the Akt/mTOR/p70S6K-mediated Autophagy Pathway
    Pengjuan Xu, ZIXUAN WU, YANFEI PENG, JING GAO, Fang Zheng, Junzhen Tan, Jing Xu, TAO WANG · 2022 · Anais da Academia Brasileira de Ciências
67. PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
    Peter Bloomingdale, Daniela Bumbaca Yadav, Jonathan A. Sugam, Steven M. Grauer, Brad E. Smith, S. V. Antonenko, Michael Judo, Glareh Azadi, Ka Lai Yee · 2022 · Frontiers in Pharmacology
68. The Role of Dietary Lipids in Cognitive Health: Implications for Neurodegenerative Disease
    Sakshi Hans, Alexandra Karadimou, John Joseph Mulvihill, Andreas Martin Grabrucker, Ioannis Zabetakis · 2022 · Biomedicines
69. Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications
    Hedieh Shahpasand‐Kroner, Ibrar Ahmed Siddique, Ravinder Malik, Gabriel R. Linares, Magdalena I. Ivanova, Justin K. Ichida, Tatjana Weil, Jan Münch, Elsa Sánchez‐García, Frank‐Gerrit Klärner et al. · 2022 · Pharmacological Reviews
70. The Pursuit of the “Inside” of the Amyloid Hypothesis—Is C99 a Promising Therapeutic Target for Alzheimer’s Disease?
    Nobumasa Takasugi, Masato Komai, Nanaka Kaneshiro, Atsuya Ikeda, Yuji Kamikubo, Takashi Uehara · 2023 · Cells
71. Prion-like strain effects in tauopathies
    Zhuang Zhuang Han, Sang‐Gyun Kang, Luis Arce, David A. Westaway · 2022 · Cell and Tissue Research
72. Comparing machine learning‐derived MRI‐based and blood‐based neurodegeneration biomarkers in predicting syndromal conversion in early AD
    Yuan Cai, Xiang Fan, Lei Zhao, Wanting Liu, Yishan Luo, Alexander Yuk Lun Lau, Lisa Wing Chi Au, Lin Shi, Bonnie Y. K. Lam, Ho Ko et al. · 2023 · Alzheimer s & Dementia
73. Synergistic Neuroprotective Effects of a Natural Product Mixture against AD Hallmarks and Cognitive Decline in Caenorhabditis elegans and an SAMP8 Mice Model
    Christian Griñán‐Ferré, Aina Bellver‐Sanchís, Mónica Olivares-Martín, Óscar Bañuelos, Mercè Pallàs · 2021 · Nutrients
74. Zn2+-responsive palladium nanoclusters synergistically manage Alzheimer’s disease through neuroprotection and inhibition of oxidative stress
    Xiaoyu Yuan, Ran Tang, Zhi Jia, Yutong Chen, Jie Liu, Yanan Liu · 2023 · Chemical Engineering Journal
75. Gamma neuromodulation improves episodic memory and its associated network in amnestic mild cognitive impairment: a pilot study
    Kevin T. Jones, Courtney L. Gallen, Avery E. Ostrand, Julio C. Rojas, Peter E. Wais, James Fraser Rini, Brandon Chan, Argentina Lario Lago, Adam L. Boxer, Min Zhao et al. · 2023 · Neurobiology of Aging
76. NeuroEPO plus (NeuralCIM®) in mild-to-moderate Alzheimer’s clinical syndrome: the ATHENEA randomized clinical trial
    Saily Sosa Pérez, Giosmany Bringas, Nelky Urrutia Amable, Ana Ibis Peñalver, Danay López, Evelio González Dalmau, Ana Fernández, Zenaida Milagros Hernández-Díaz, Ariel Vina-Rodrı́guez, Yamilé Peña et al. · 2023 · Alzheimer s Research & Therapy
77. Do microbes play a role in Alzheimer's disease?
    Zoë A. P. Williams, Léonie Láng, Sarah Nicolas, Gerard A. Clarke, John F. Cryan, David Vauzour, Yvonne M. Nolan · 2024 · Microbial Biotechnology
78. Treatment effects on event-related EEG potentials and oscillations in Alzheimer's disease
    Görsev Yener, Duygu Hünerli Gündüz, Ebru Yıldırım, Tuba Aktürk, Canan Başar‐Eroğlu, Laura Bonanni, Claudio Del Percio, Francesca R Farina, Raffaele Ferri, Bahar Güntekin et al. · 2022 · International Journal of Psychophysiology
79. Neurotechnology’s Prospects for Bringing About Meaningful Reductions in Neurological Impairment
    David F. Putrino, John W. Krakauer · 2022 · Neurorehabilitation and neural repair
80. Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer’s disease
    Yan Lian, Yujuan Jia, Joelyn Wong, Xin‐Fu Zhou, Weihong Song, Junhong Guo, Colin Louis Masters, Yan‐Jiang Wang · 2023 · Molecular Psychiatry
81. What have we learnt from past failures in Alzheimer’s disease drug discovery?
    Cacabelos, Ramón · 2022 · Expert Opinion on Drug Discovery
82. Genetic Therapies for Alzheimer’s Disease: A Scoping Review
    Matthew J. Lennon, Grant Rigney, Vanessa Raymont, Perminder Singh Sachdev · 2021 · Journal of Alzheimer s Disease
83. Preclinical Alzheimer’s dementia: a useful concept or another dead end?
    Ruth E. Mark, Yvonne Brehmer · 2022 · European Journal of Ageing
84. Personalized Management and Treatment of Alzheimer’s Disease
    Ramón Cacabelos, Vinogran Naidoo, Olaia A. Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego, Juan C. Carril · 2022 · Life
85. A review and analysis of key biomarkers in Alzheimer’s disease
    Zhihao Zhang, Xiangtao Liu, Suixia Zhang, Zhixin Song, Ke Lu, Wenzhong Yang · 2024 · Frontiers in Neuroscience
86. Pharmacologic and Nutritional Interventions for Early Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
    Baoqi Zeng, Chunbian Tang, Junjian Wang, Qingqing Yang, Qingcuo Ren, Xiaozhi Liu · 2024 · Journal of Alzheimer s Disease
87. A Scoping Review of Alzheimers Disease Hypotheses: An Array of Uni- and Multi-Factorial Theories
    Simon Duchesne, Louis‐Simon Rousseau, Florence Belzile, Laurie‐Ann Welch, Béatrice Cournoyer, Marianne Arseneau, Véronick Lapierre, Sara‐Maude Poulin, Olivier Potvin, Carol Hudon · 2024 · Journal of Alzheimer s Disease
88. Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments
    George P. Paraskevas, Elisabeth N. Kapaki · 2021 · Brain Sciences
89. A tough trek in the development of an anti-amyloid therapy for Alzheimer's disease: Do we see hope in the distance?
    Jin Jun Luo, William Wallace, John W. Kusiak · 2022 · Journal of the Neurological Sciences
90. AD and non‐AD mediators of the pathway between the APOE genotype and cognition
    Emma Nichols, Adam M. Brickman, Kaitlin Blackstone Casaletto, Kristen Dams-O’Connor, Kristen M. George, Raj G. Kumar, Priya Palta, Jennifer S. Rabin, Claudia Liliana Satizábal, Julie A. Schneider et al. · 2022 · Alzheimer s & Dementia
91. The supersaturation perspective on the amyloid hypothesis
    Diana Portugal Barron, Zhefeng Guo · 2023 · Chemical Science
92. Antibodies Raised Against an Aβ Oligomer Mimic Recognize Pathological Features in Alzheimer’s Disease and Associated Amyloid-Disease Brain Tissue
    Adam G. Kreutzer, Chelsea Marie T. Parrocha, Sepehr Haerianardakani, Gretchen Guaglianone, Jennifer T. Nguyen, Michelle N. Diab, William H. Yong, Mari A. Perez-Rosendahl, Elizabeth Head, James S. Nowick · 2023 · ACS Central Science
93. Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
    Ramón Cacabelos, Vinogran Naidoo, Olaia A. Martínez-Iglesias, Lola Corzo, Natalia Cacabelos, Rocío Pego, Juan C. Carril · 2022 · Methods in molecular biology
94. Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model
    Reinitz, Felicia, Chen, Elizabeth Y, Nicolis di Robilant, Benedetta, Chuluun, Bayarsaikhan, Antony, Jane, Jones, Robert C, Gubbi, Neha, Lee, Karen, Ho, William Hai Dang, Kolluru, Sai Saroja et al. · 2022 · eLife
95. Pharmacologic reversal of advanced Alzheimer’s disease in mice and identification of potential therapeutic nodes in human brain
    Kalyani Chaubey, Edwin Vázquez‐Rosa, Sunil Jamuna Tripathi, Min‐Kyoo Shin, Youngmin Yu, Matasha Dhar, Suwarna Chakraborty, Mai Yamakawa, Xinming Wang, Preethy S. Sridharan et al. · 2025 · Cell Reports Medicine
96. Implications of FDA Approval of a First Disease-Modifying Therapy for a Neurodegenerative Disease on the Design of Subsequent Clinical Trials
    Joshua D. Grill, Jason H. Karlawish · 2021 · Neurology
97. Role of CRF and the hypothalamic‐pituitary‐adrenal axis in stroke: revisiting temporal considerations and targeting a new generation of therapeutics
    Daniel Andrew Lichlyter, Zachary A. Krumm, Todd Eliot Golde, Sylvain Doré · 2022 · FEBS Journal
98. Effects of α5 GABAA receptor modulation on social interaction, memory, and neuroinflammation in a mouse model of Alzheimer's disease
    Jovana Aranđelović, Anja Santrač, Bojan Batinić, Lidija Todorović, Vladimir Stevanović, V. V. N. Phani Babu Tiruveedhula, Dishary Sharmin, Farjana Rashid, Boban Stanojević, James Minton Cook et al. · 2022 · CNS Neuroscience & Therapeutics
99. Jiedu-Yizhi Formula Alleviates Neuroinflammation in AD Rats by Modulating the Gut Microbiota
    Jiale Wang, Xiaoting Zhu, Yuhui Li, Wenping Guo, Mingquan Li · 2022 · Evidence-based Complementary and Alternative Medicine
100. Evaluating the effects of glucagon-like peptide-1 receptor agonists on cognitive function in Alzheimer’s disease: A systematic review and meta-analysis
     Zeyu Bi, Ling Wang, Wei Wang · 2023 · Advances in Clinical and Experimental Medicine